Acetylleucine (N-acetyl-leucine) is a modified leucine amino acid.

Acetylleucine
Stereo, skeletal model of acetylleucine (S)
(S)-(−)-N-Acetyl-leucine
Names
IUPAC name
2-Acetamido-4-methylpentanoic acid[1]
Other names
N-Acetylleucine; N-Acetyl-L-Leucine
Identifiers
3D model (JSmol)
1724849 (S)-(−)
ChEBI
ChEMBL
ChemSpider
EC Number
  • Racemic: 202-734-9
985259 (S)-(−)
KEGG
MeSH acetylleucine
UNII
  • InChI=1S/C8H15NO3/c1-5(2)4-7(8(11)12)9-6(3)10/h5,7H,4H2,1-3H3,(H,9,10)(H,11,12) checkY
    Key: WXNXCEHXYPACJF-UHFFFAOYSA-N checkY
  • Racemic: CC(C)CC(NC(C)=O)C(O)=O
Properties
C8H15NO3
Molar mass 173.212 g·mol−1
Appearance White crystals
Melting point −115 to −113 °C; −175 to −172 °F; 158 to 160 K
log P −0.265
Acidity (pKa) 3.666
Basicity (pKb) 10.331
Pharmacology
N07CA04 (WHO)
Related compounds
Related compounds
ENU
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).

Two forms are commercialized: N-acetyl-DL-leucine (sold under the brand Tanganil, among others, and used in the treatment of vertigo[2]) and N-acetyl-L-leucine (levacetylleucine, sold under the brand name Aqneursa, and used for the treatment of neurological manifestations of Niemann-Pick disease type C).[3]

References

edit
  1. ^ "N-Acetyl-DL-leucine". PubChem Open Chemistry Database. Retrieved 26 March 2017.
  2. ^ "N07CA04 (acetylleucine)". WHO Collaborating Centre for Drug Statistics Methodology. Norwegian Institute of Public Health. 19 December 2016. Retrieved 26 March 2017.
  3. ^ Oertel WH, Janzen A, Henrich MT, Geibl FF, Sittig E, Meles SK, et al. (2 September 2024). "Acetyl-DL-leucine in two individuals with REM sleep behavior disorder improves symptoms, reverses loss of striatal dopamine-transporter binding and stabilizes pathological metabolic brain pattern—case reports". Nature Communications. 15 (1): 7619. doi:10.1038/s41467-024-51502-7. ISSN 2041-1723. PMC 11369233. PMID 39223119.